BeOne Medicines Ltd. (ONC)
379.69
+7.71
(+2.07%)
USD |
NASDAQ |
Aug 25, 14:03
BeOne Medicines Enterprise Value : 35.54B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 35.54B |
| August 21, 2026 | 35.80B |
| August 20, 2026 | 35.25B |
| August 19, 2026 | 36.05B |
| August 18, 2026 | 35.25B |
| August 17, 2026 | 34.55B |
| August 14, 2026 | 32.99B |
| August 13, 2026 | 33.88B |
| August 12, 2026 | 34.19B |
| August 11, 2026 | 34.22B |
| August 10, 2026 | 34.19B |
| August 07, 2026 | 33.07B |
| August 06, 2026 | 31.15B |
| August 05, 2026 | 30.91B |
| August 04, 2026 | 30.44B |
| August 03, 2026 | 29.48B |
| July 31, 2026 | 29.71B |
| July 30, 2026 | 30.34B |
| July 29, 2026 | 30.88B |
| July 28, 2026 | 31.21B |
| July 27, 2026 | 30.74B |
| July 24, 2026 | 30.74B |
| July 23, 2026 | 30.83B |
| July 22, 2026 | 30.12B |
| July 21, 2026 | 29.99B |
| Date | Value |
|---|---|
| July 20, 2026 | 29.14B |
| July 17, 2026 | 29.29B |
| July 16, 2026 | 29.86B |
| July 15, 2026 | 29.21B |
| July 14, 2026 | 28.72B |
| July 13, 2026 | 28.45B |
| July 10, 2026 | 27.91B |
| July 09, 2026 | 28.34B |
| July 08, 2026 | 28.24B |
| July 07, 2026 | 28.98B |
| July 06, 2026 | 29.03B |
| July 02, 2026 | 27.80B |
| July 01, 2026 | 27.08B |
| June 30, 2026 | 26.48B |
| June 29, 2026 | 26.88B |
| June 26, 2026 | 25.84B |
| June 25, 2026 | 25.38B |
| June 24, 2026 | 25.56B |
| June 23, 2026 | 25.46B |
| June 22, 2026 | 25.02B |
| June 18, 2026 | 24.85B |
| June 17, 2026 | 24.08B |
| June 16, 2026 | 24.21B |
| June 15, 2026 | 24.65B |
| June 12, 2026 | 24.27B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| CRISPR Therapeutics AG | 3.936B |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 172.21M |
| Idorsia Ltd. | 3.462B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 237.40M |
| Revenue (Quarterly) | 1.708B |
| Total Expenses (Quarterly) | 1.470B |
| EPS Diluted (Quarterly) | 2.050 |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | 13.90% |
| Earnings Yield | 1.50% |
| Operating Earnings Yield | 2.11% |
| Normalized Earnings Yield | 1.577 |